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Abstract
Objective:  To  evaluate  the  incidence  of  small  bowel  bacterial  overgrowth  (SBBO)  in  children
treated with  omeprazole,  and  to  test  whether  probiotics  inﬂuence  the  incidence.
Methods: A  double-blinded,  placebo-controlled  trial  was  performed  in  70  children  treated
orally during  four  weeks  with  20  mg  omeprazole  per  day.  Lactobacillus  rhamnosus  R0011
(1.9 ×  109 cfu)  and  Lactobacillus  acidophillus  R0052  (0.1  ×  109 cfu)  were  simultaneously  given
daily  to  36  subjects  (probiotic  group),  while  34  subjects  received  placebo  (placebo  group).  The
diagnosis  of  SBBO  was  based  on  the  development  of  suggestive  symptoms,  in  combination  with
a  positive  glucose  breath  test.
Results: After  one  month  of  proton  pump  inhibitor  (PPI)  treatment,  30%  (21/70)  had  a  positive
breath test  suggesting  SBBO;  of  these  62%  were  symptomatic.  Five  children  developed  SBBO-like
symptoms,  but  had  a  negative  breath  test;  and  44  (63%)  were  symptom  free  and  had  a  negative
breath  test.  There  was  no  difference  in  the  incidence  of  positive  breath  tests  in  the  probiotic
versus  the  placebo  group  (33%  vs  26.5%;  p  =  0.13).
Conclusions:  Since  symptoms  suggesting  SBBO  developed  in  26%  of  PPI-treated  children,  and
since the  glucose  breath  test  was  abnormal  in  72%  of  these,  this  side-effect  should  be  more
frequently  considered.  The  probiotic  tested  did  not  decrease  the  risk  to  develop  SBBO.
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PALAVRAS-CHAVE
Teste  de  hidrogênio
no  ar  expirado;
Diarreia;
Flatulência;
Omeprazol;
Probiótico;
Inibidor  da  bomba  de
prótons;
Supercrescimento
bacteriano do
intestino delgado
Um  ensaio  randomizado  duplo-cego  e  controlado  por  placebo  com  probióticos  em
casos  de  supercrescimento  bacteriano  no  intestino  delgado  em  crianc¸as  tratadas  com
omeprazol
Resumo
Objetivo:  Avaliar  a  incidência  de  SBID  em  crianc¸as  tratadas  com  omeprazol  e  testar  se  os
probióticos inﬂuenciam  essa  incidência.
Métodos: Um  ensaio  duplo-cego  controlado  por  placebo  foi  realizado  em  70  crianc¸as  tratadas
oralmente, durante  4  semanas,  com  20  mg  de  omeprazol  por  dia.  Desses,  36  indivíduos  rece-
beram  diária  e  simultaneamente  Lactobacillus  rhamnosus  R0011  (1,9  ×  109 cfu)  e  Lactobacillus
acidophillus  R0052  (0,1  ×  109 cfu)  (grupo  probiótico),  enquanto  34  receberam  placebo  (grupo
placebo).  O  diagnóstico  de  SBID  teve  como  base  o  desenvolvimento  de  sintomas  sugestivos  em
combinac¸ão  com  um  teste  respiratório  com  glicose  positivo.
Resultados:  Após  um  mês  de  tratamento  com  IBP,  30%  (21/70)  apresentaram  um  teste  respi-
ratório positivo  sugerindo  SBID;  desses,  62%  foram  sintomáticos.  Cinco  crianc¸as  desenvolveram
sintomas  parecidos  com  os  de  SBID,  mas  apresentaram  um  teste  respiratório  negativo;  44  (63%)
não  apresentavam  sintomas  e  tiveram  teste  respiratório  negativo.  Não  houve  diferenc¸a na
incidência  de  testes  respiratórios  positivos  no  grupo  probiótico  em  comparac¸ão  ao  grupo  placebo
(33%  em  comparac¸ão  a  26,5%;  p:  0,13).
Conclusões:  Como  houve  sintomas  sugestivos  de  SBID  em  26%  das  crianc¸as  tratadas  com  IBP  e  o
teste respiratório  com  glicose  deu  resultados  anormais  em  72%  delas,  esse  efeito  colateral  deve
ser  levado  em  considerac¸ão  com  mais  frequência.  O  probiótico  testado  não  reduziu  o  risco  de
desenvolver  SBID.
© 2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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roton  pump  inhibitors  (PPIs)  such  as  omeprazole  are
dministered in  gastrointestinal  diseases  such  as  gas-
roesophageal reﬂux  disease,  gastric  or  duodenal  ulcer,
ollinger-Ellison syndrome,  and  eradication  therapy  for
elicobacter pylori.1--3 The  gastric  acid  secretory  inhibitor
ffect of  PPIs  is  much  more  potent  than  the  effect  of  his-
amine receptor  antagonists.2,4
Small  bowel  bacterial  overgrowth  (SBBO)  is  a  condi-
ion marked  by  an  increased  number  of  intestinal  bacteria
nd a  change  in  bacterial  composition  in  the  gastroin-
estinal tract.5,6 Risk  factors  for  SBBO  are  long  term
ypo/achlorhydria  (as  induced  by  PPI),  intestinal  anatom-
cal abnormalities  (such  as  diverticulum,  ﬁstula,  stricture,
dhesion, removal  of  ileocecal  ﬂap),  hypomotility  (such
s in  diabetic  neuropathy,  scleroderma),  and  severe
mmunodeﬁciency.5,6 The  diagnosis  of  SBBO  is  based  on
linical manifestations  and  on  the  results  of  a  glucose
reath test.  Clinical  manifestations  of  SBBO  are  marked  by
ymptoms such  as  abdominal  pain,  ﬂatulence,  frequent  ﬂa-
us, diarrhea  or  constipation,  and  steatorhea.5--7 In  chronic
onditions, SBBO  can  cause  anemia,  failure  to  thrive,  neu-
opathy, tetany,  and  paresthesia.5--7 The  golden  standard  to
iagnose SBBO  is  to  culture  intestinal  aspirate.  However,  the
atter is  not  performed  in  routine  practice  because  of  its
nvasive nature,  its  difﬁculty,  its  relatively  high  cost  and
ime consumption,  and  its  inability  to  diagnose  SBBO  in
he distal  area  of  the  intestine.5--9 The  Rome  Consensus  of
009 recommended  the  glucose  hydrogen  breath  test  as  the
T
t
best  diagnostic  tool  for  SBBO,  since  it  is  non-invasive,  easy
o perform,  has  direct  results,  and  has  a  good  diagnostic
ccuracy.8
Probiotics  are  living  microorganisms  which,  if  ingested
n adequate  amounts,  will  result  in  a  health  beneﬁt  for
he host.10 A  role  for  probiotics  in  many  diseases  such  as
nfectious diarrhea,  antibiotic  associated  diarrhea,  atopy,
nd constipation  has  been  suggested.11--13 Efﬁcacy  has  also
een reported  for  some  strains,  such  as  Lactobacillus  shi-
ota, in  SBBO.14 Probiotics’  mechanisms  of  action  consist
f competition  with  harmful  bacteria,  synthesis  of  antimi-
robial conjugate  (bacteriocin,  lactic  acid,  organic  acid,
icrosin, reuterin,  and  volatile  fatty  acid),  stimulation
f the  immune  response,  and  stimulation  of  the  intesti-
al epithelium  through  production  of  short  chain  fatty
cids.15--19 Until  now,  studies  on  the  role  of  probiotics
n prevention  and  therapy  of  SBBO  in  children  are  very
imited.
The aims  of  this  study  were  to  test  whether  PPIs  induce
BBO in  children,  and  to  evaluate  whether  the  probiotic
trains tested  can  prevent  the  development  of  SBBO.
ethods
tudy  design  and  subjectshis  double-blinded,  placebo-controlled  randomized  clinical
rial was  conducted  in  children  ≥  5  years  old  seen  mainly
ecause of  complaints  of  epigastric  pain  in  the  Outpatient
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Clinic  of  the  Cipto  Mangunkusumo  Hospital.  When  it  was
decided, on  clinical  grounds,  that  the  presenting  symptoms
justiﬁed a  therapeutic  trial  with  omeprazole,  and  in  the
absence of  exclusion  criteria,  a  glucose  breath  test  was  per-
formed to  rule  out  SBBO  prior  to  PPI-therapy.
All  the  subjects  were  treated  with  20  mg  of  oral  omepra-
zole daily  for  four  weeks.  Patients  swallowed  the  intact
omeprazole capsule;  patients  with  difﬁculties  to  swallow
the capsule  were  allowed  to  open  it  and  swallow  the  micro-
granules in  media  such  as  orange  juice  or  berry  juice.
Furthermore, the  patients  were  randomized  in  two  groups:
group A  (probiotic  group)  received  one  probiotic  capsule  per
day during  four  weeks,  while  group  B  (control  group)  was
given a  placebo  capsule.  The  probiotic  used  is  Lacidoﬁl®,
which contains  1.9  ×  109 cfu  Lactobacillus  rhamnosus  R0011
and 0.1  ×  109 cfu  Lactobacillus  acidophillus  R0052.  A  cold
chain for  the  administration  of  the  probiotic  was  preserved,
as the  probiotics  were  stored  in  a  cooler  and  transported
using a  cold  chain  bag  with  gel  ice  packs  inside.
The  following  patients  were  excluded:  known  SBBO;
treatment with  anti-acid  agents  or  antibiotics  during  the
past two  weeks;  immune  suppression  (steroid  treatment,
antituberculosis therapy,  antiretroviral,  or  cytostatics);  or
warfarin, phenytoin  or  diazepam  use.
Observation  for  medication  compliance  (PPI  and  probio-
tic/placebo) was  performed  twice  a  week  through  phone,
by asking  the  parents  about  compliance.  Subjects  who  did
not take  their  medication  during  at  least  three  days  during
the four-week  intervention  period  were  considered  as  ‘‘poor
compliant’’. A second  glucose  breath  test  was  performed
four to  ten  days  after  the  end  of  therapy.Hydrogen  breath  test8,9,20
The  patients  fasted  for  ten  to  12  hours,  and  brushed  their
teeth in  the  morning  prior  to  the  examination.  The  breath
w
(
7
Table  1  Characteristics  of  subjects  and  its  distribution  between  
Characteristics  of  subjects  
P
Age  (years)a
Median 1
Range 
Genderb
Male  
Female 3
Nutritional statusc
Good  (CDC  Curve,  BW/BL  >  90%-100%) 1
Undernourished  (CDC  Curve,  BW/BL  70%-90%) 1
Overweight (BMI  >  P85)  
Obese (BMI  >  P95)  
BMI, body mass index; BW/BL, birth weight/birth length; CDC, Centers
a Mann-Whitney test.
b Fisher’s exact test.
c McNemar’s test.383
est  started  by  measuring  the  baseline  hydrogen;  the  latter
ad to  be  <  10  ppm  to  be  considered  as  normal  (Gastrolyzer2,
edfont Scientiﬁc  Ltd.;  distributor  for  Indonesia:  CV  Andalan
atara, Jakarta).  A  normal  baseline  hydrogen  value  was  nec-
ssary to  be  eligible  for  inclusion.  The  patients  ingested
 g/kg  body  weight  glucose  (maximum  of  50  g),  which  was
iluted in  10  mL/kg  body  weight  water  (maximum  250  mL).
he hydrogen  level  was  measured  every  15  minutes  up  to  two
ours after  ingestion  of  the  glucose.  Every  clinical  symptom
r complaint  during  the  breath  test  was  recorded.  A  posi-
ive breath  test  was  deﬁned  as  an  increase  of  >  10  ppm  from
aseline.21
Patients,  parents,  and  all  study  participants  were
linded. Study  evaluators  were  blinded  by  omission  of  the
ame of  patient  on  the  hydrogen  breath  test  data.  The
lacebo was  made  by  the  Pharmacy  Department  of  the  Fac-
lty of  Medicine  of  the  University  of  Indonesia.
Statistical  analysis  was  performed  with  the  Statistical
ackage for  Social  Sciences  (SPSS)  version  17.  The  proto-
ol was  approved  by  the  local  ethical  committee,  and  all
arents signed  an  informed  consent.
esults
nitially,  73  patients  were  included  in  the  study.  However,
ome visits  found  that  three  patients  did  not  have  a  refrig-
rator at  home.  Since  it  was  not  known  whether  they  were
n the  probiotic  or  the  placebo  group,  and  since  the  probio-
ic needed  to  be  conserved  in  a cool  environment,  these
atients were  considered  as  dropout.  Thus,  data  of  70
atients were  available  for  analysis.  Most  of  the  subjects
ere female  (61/70),  with  a  good  nutritional  status  (39/70)
Table 1).
The mean  age  was  13.5  years  (range  6-17  years).  Of  the
0 subjects,  36  were  included  in  the  probiotic  and  34  in  the
groups.
Group  p
robiotics  Placebo
0.108
3.5  14
6  -  17  12--17  1.00
5  4  0.176
1  30
7  22
5  8
3  3
1  1
 for Disease Control and Prevention.
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Table  2  Hydrogen  breath  test  results  related  to  probiotic  or  placebo,  regardless  of  symptoms.
SBBO  Total
+  -
Omeprazole  +  probiotics  12  (33%)  24  (67%)  36
Omeprazole  +  placebo 9  (26%) 25 (73%) 34
Total 21 49  70
p = 0.13.
SBBO, small bowel bacterial overgrowth.
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(IBS).23 Ratuapli  et  al.  published  recently  a  large  retro-
spective analysis  on  the  effect  of  PPI  on  SBBO  in  adults.21
Overall,  the  authors  reported  that  PPI  did  not  induce  SBBO;
Table  4  Complaints  and  therapy  response.
Characteristics  of  subjects  Proportion
Initial  complaints
Epigastric  pain  70  (70/70)
Nausea  65  (65/70)
Vomiting  10  (10/65)
Gastrointestinal  bleeding* 3  (3/10)
Flatulence  30  (30/70)
Limitation  of  activity  45  (45/70)
Medication  compliance
Yes 41  (41/70)lacebo  group.  Medication  compliance  was  rather  low  since
‘good compliance’’  was  only  observed  in  41/70  patients
59%). Compliance  was  ‘‘poor’’  in  29  patients;  11  complied
oorly with  the  probiotic  or  placebo,  and  18  complied  poorly
ith the  PPI.  Nevertheless,  66/70  (94%)  of  the  patients
aid to  be  symptom-free  or  to  have  a  clinically  signiﬁcant
mprovement of  their  symptoms  after  the  intervention.  Only
/70  (6%)  said  to  have  not  improved.
In  total,  18  subjects  developed  symptoms  suggesting  pos-
ible SBBO;  in  13  of  these,  the  second  breath  test  suggested
BBO. 16  of  these  18  patients  had  a  ‘‘good  PPI  compliance’’.
ccording to  the  results  of  the  breath  test  (regardless  of  the
resence/absence of  symptoms),  SBBO  was  found  in  21/70
30%) of  the  patients,  with  a  slight  trend  of  more  SBBO  in  the
robiotic group  (33%;  12/36)  than  in  the  placebo  group  (26%;
/34) (p  = 0.13,  Table  2).  From  the  21  subjects  with  positive
ydrogen breath  test,  13  subjects  presented  recurrent  SBBO
ymptoms  during  therapy  (Table  3),  while  eight  were  asymp-
omatic. Finally,  44/70  (63%)  patients  were  asymptomatic
nd had  a  negative  glucose  breath  test  under  PPI  treat-
ent. Five  patients  had  symptoms  suggesting  SBBO,  but  had
 normal  breath  test  result.  13/21  (62%)  developed  at  least
ne symptom  compatible  with  SBBO  during  PPI  therapy;  four
19%  of  the  total  group,  or  31%  of  the  symptomatic  group)
resented more  than  one  symptom  (Table  4).  Two  subjects
eveloped extensive  SBBO  with  diarrhea,  abdominal  pain,
nd ﬂatulence.
iscussionhis  was  the  ﬁrst  study  conducted  in  children  that  focused
n SBBO  incidence  with  PPI  treatment  as  single  risk  factor,
Table  3  Number  of  children  with  symptoms  suggesting
small bowel  bacterial  overgrowth  (SBBO)  and  result  of  the
second  glucose  hydrogen  breath  test.
Symptoms  suggesting  SBBO
Yes  No
Result  H2 breath  test
Positive  13  8  21
Negative 5  44  49
18  52
p < 0.001 (chi squared test).nd  also  evaluated  the  role  of  probiotics  in  prevention  of
BBO. The  results  suggest  a  placebo-effect  of  the  PPI,  since
8/70 were  not  compliant;  only  four  reported  no  signiﬁcant
mprovement, all  of  which  in  the  non-compliant  group.  A
ohort study  by  Boissieu  et  al.  in  53  children,  aged  between
 months  and  12  years,  with  complaints  of  chronic  diarrhea,
bdominal pain,  or  both,  reported  SBBO  as  a  frequent  cause
34%), especially  before  the  age  of  2  years.22 Scarpellini
t al.  reported  the  prevalence  of  SBBO  to  be  as  high  as  65%
n children  aged  3  to  16  years  with  irritable  bowel  syndromeNo 29  (29/70)
Therapy  response
Cured 46  (46/70)
Improvement  20  (20/70)
No improvement 4  (4/70)
SBBO symptoms  during  therapy  in  groups  with
positive  hydrogen  breath  test
Diarrhea  1  (1/21)
Mid abdominal  pain  1  (1/21)
Flatulence  5  (5/21)
Frequent  ﬂatus  1  (1/21)
Constipation  1  (1/21)
Flatulence  and  abdominal  pain  2  (2/21)
Diarrhea,  ﬂatulence,  and  abdominal  pain  2  (2/21)
No complaints  8  (8/21)
SBBO, small bowel bacterial overgrowth.
* Complaints of vomiting mixed with brown spots.
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HBT-positivity  was  associated  with  older  age  and  use  of
antidiarrheal products.21 However,  Del  Pioano  almost  simul-
taneously conﬁrmed  a  strong  bacterial  overgrowth  in  the
stomach and  duodenum  of  adults  treated  with  PPI,  increas-
ing with  treatment  duration.24 The  glucose  breath  test  at
baseline was  normal  in  all  children  included  in  the  present
study.
In the  present  study,  the  subjects  involved  were  chil-
dren with  a  mean  age  of  13.5  years,  who  presented  with
the single  chief  complaint  of  epigastric  pain.  The  propor-
tion of  girls  in  this  study  was  much  higher  than  boys,  but
gender was  normally  distributed  in  both  groups  (p  =  1.00).
This difference  can  be  explained  by  coincidence,  by  the
fact that  there  are  more  girls  than  boys  in  this  age
group in  Jakarta,  and/or  by  the  fact  that  functional  gas-
trointestinal complaints  might  be  more  frequent  in  girls.
However, this  striking  difference  needs  further  investiga-
tion.
Sixty-two percent  of  the  subjects  with  positive  hydro-
gen breath  test  developed  SBBO  symptoms  during  therapy
and during  the  breath  test  (Tables  2  and  3).  This  is  in
agreement with  studies  in  children,  which  have  showed
SBBO to  be  a  common  cause  of  abdominal  pain  and
diarrhea in  children.22 16  of  18  children  with  SBBO  symp-
toms had  a  ‘‘good  compliance  to  PPI’’,  reinforcing  the
argument of  PPIs  as  a  cause  of  SBBO.  To  the  authors’
knowledge, studies  on  SBBO  incidence  in  children  related
to omeprazole  therapy  have  not  been  performed;  how-
ever, this  incidence  was  reported  to  be  as  high  as  45%
to 56%  in  adult  subjects.25--27 The  difference  in  SBBO  inci-
dence in  the  present  study  (19%)  with  that  of  the  adult
studies can  be  explained  by  several  factors,  such  as  dif-
ference in  dosage  and  duration  of  omeprazole  treatment,
different characteristics  of  the  patients,  and  different  diag-
nostic methods.  This  differs  from  the  characteristics  of
adult studies,  in  which  the  mean  age  of  the  patients
is over  50  years.  SBBO  incidence  is  higher  later  in  life
due to  the  decline  in  immunity  and  intestinal  motility,  as
well as  hypo/achlorhydria.5,6,21 The  incidence  of  SBBO  and
hypo/achlohydria in  a  senior  age  group  (mean  age  84  years)
was reported  to  be  80%.28 The  high  metabolism  of  omepra-
zole in  certain  age  ranges  (between  1  and  6  years  and  13
and 16  years),  which  is  in  line  with  the  subjects’  age  in
this study,  may  contribute  to  the  lower  incidence  of  SBBO  in
adolescents.29
The  duration  of  omeprazole  therapy  is  directly  related
with SBBO  incidence.24 This  ﬁnding  is  also  supported  by  a
study by  Lombardo  et  al.,  which  showed  that  SBBO  incidence
is signiﬁcantly  higher  in  the  group  with  PPI  therapy  for  over
13 months  (p  <  0.001).30 In  the  present  study,  SBBO  incidence
was evaluated  in  children  treated  with  20  mg  of  omeprazole
daily for  four  weeks.  The  dosage  and  duration  of  therapy
is smaller  in  the  present  study  than  in  the  reports  in  adults
using 20  to  40  mg  of  omeprazole  for  ≥  four  weeks,  up  to  9.5
months.25--27
The  probiotic  strains  administered  did  not  decrease  the
development of  SBBO.  However,  probiotics  are  a  thera-
peutic option  of  potential  beneﬁt.31 Lactobacillus  shirota
was shown  to  be  effective  in  altering  fermentation  pat-
terns in  the  small  bowel,  consistent  with  SBBO  reduction.14
Del  Piano  et  al.  demonstrated  that  four  probiotic  strains
with a  marked  antagonistic  activity  towards  ﬁve  E.  coli
F
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acteria  and  an  effective  amount  of  N-acetylcysteine  (NAC)
educed bacterial  overgrowth  in  long-term  PPI-treated
ubjects.24 A  signiﬁcant  decrease  in  fecal  enterococci,
otal coliforms,  E.  coli,  molds,  and  yeasts  in  subjects
reated with  PPIs  was  recorded  at  the  end  of  the  probiotic
upplementation.24
The  hydrogen  breath  test  measures  the  amount  of
xpired hydrogen  in  the  expired  air  after  fasting  for  ten
o 12  hours,  followed  by  ingestion  of  glucose  substrate.  If
he glucose  is  not  absorbed,  but  metabolized  by  intesti-
al bacteria,  intraluminal  gasses  such  as  hydrogen  (H2),
ethane (CH4),  and  carbon  dioxide  (CO2)  will  be  pro-
uced, which  can  be  measured  by  the  breath  test.20 The
lucose hydrogen  breath  test  is  reported  to  have  a  sensi-
ivity, speciﬁcity,  and  diagnostic  accuracy  of  62.5%,  81.8%,
nd 71.7%,  respectively.  According  to  the  Rome  consen-
us of  2009,  the  glucose  hydrogen  breath  test  is  the
ecommended diagnostic  tool  in  patients  with  suspected
BBO.8
In  the  present  study,  ﬁve  subjects  developed  SBBO-like
ymptoms but  had  a negative  hydrogen  breath  test.  The
lucose breath  test  can  be  false  negative  due  to  intesti-
al colonization  with  non-hydrogen  producing  bacteria,
r because  the  level  of  hydrogen  production  is  not  high
nough to  be  detected,  and  SBBO  is  occurring  in  the  dis-
al part  of  ileum  (where  all  the  glucose  has  already  been
bsorbed).20,32 According  to  literature,  the  prevalence  of
olonization with  non-hydrogen  producing  bacteria  varies
rom 2%  to  43%.33 However,  non-hydrogen  producing  bacte-
ia produce  methane,  resulting  in  an  increase  of  expired
ethane despite  normal  hydrogen.  Levit  et  al.  reported
hat 36.4%  of  adults  (aged  18  to  88  years)  with  SBBO  had
 methane-producing  gastrointestinal  colonization.34 Since
he device  used  in  the  present  study  only  measures  hydrogen
nd not  methane,  further  information  on  this  aspect  can-
ot be  provided.  In  some  patients,  SBBO-related  symptoms
re similar  to  the  initial  presenting  symptoms.  Although  it
annot be  excluded  that  in  a  few  patients  it  was  the  ini-
ial symptoms  that  persisted,  this  is  unlikely  for  different
easons: i)  the  initial  symptoms  had  strong  improvement;  ii)
ymptoms were  reported  as  being  different;  iii)  there  was
n association  with  the  positive  breath  test.  Moreover,  16
f 18  children  with  symptoms  suggesting  SBBO  were  compli-
nt to  PPI  treatment.  The  second  breath  test  was  performed
our to  ten  days  after  stopping  PPI  therapy,  when  the  poten-
ial acid  rebound  secretion  period  caused  by  PPI  interruption
as over.35
In  conclusion,  SBBO  was  found  to  be  frequent  in  children
reated with  20  mg/day  of  omeprazole  for  four  weeks  (26%  if
nly symptoms  are  considered;  30%  if  only  results  of  hydro-
en breath  test  are  considered;  19%  if  both  symptoms  and
ositive hydrogen  breath  test  are  considered).  The  probiotic
ested did  not  prevent  the  development  of  SBBO.  Children
ho develop  symptoms  such  as  diarrhea,  abdominal  pain,
nd ﬂatulence  under  PPI  treatment  should  be  investigated
or SBBO.unding
exa  Medica  provided  free  samples  of  the  probiotic  and
lacebo.
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